Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05484622 · ClinicalTrials.gov registry record · Phase 1
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
A Phase 1 study of Astrocytoma and Oligodendroglioma, sponsored by Institut de Recherches Internationales Servier.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 17
- Study locations
NCT05484622 is a Phase 1 study of Astrocytoma and Oligodendroglioma that is active but no longer recruiting, run by Institut de Recherches Internationales Servier. The registered enrollment target is 60 participants, above the 46-participant average among 19 other Astrocytoma trials with a reported enrollment target (30% higher). The trial reports 17 study locations across 14 states.
The verdict
NCT05484622, a Phase 1 study of Astrocytoma and Oligodendroglioma, is active but no longer recruiting, sponsored by Institut de Recherches Internationales Servier.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 17
- Study locations
Study Summary
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Vorasidenib
Study Locations (17)
California
- University of California, Los Angeles (Site: 840113) - Los Angeles
- University of California, San Francisco (Site: 840149) - San Francisco
Massachusetts
- Massachusetts General Hospital (Site: 840104) - Boston
- Dana-Farber Cancer Institute (Site: 840139) - Boston
Ohio
- Cleveland Clinic - Cleveland
- Mayo Clinic Florida - Cleveland
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado - Aurora
Florida
- University of Miami (Site: 840129) - Miami
Illinois
- Northwestern University (Site: 840123) - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05484622
The ClinicalTrials.gov registry entry for NCT05484622 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 19 other Astrocytoma trials with a reported enrollment target (30% higher). The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Astrocytoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05484622 reports 17 study locations spanning 14 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05484622 about?
NCT05484622 is a clinical study titled "Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma". Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
What is the current status of trial NCT05484622?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-01-20. Estimated completion is 2027-08-30.
What conditions does trial NCT05484622 study?
This clinical trial studies the following conditions: Astrocytoma, Oligodendroglioma.
What interventions are being tested in trial NCT05484622?
The interventions under investigation include: Pembrolizumab (DRUG), Vorasidenib (DRUG).
Who is sponsoring clinical trial NCT05484622?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05484622 being conducted?
This trial has 17 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Astrocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
-
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
ACTIVE NOT RECRUITING · Phase 1
-
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.